Krishna Institute of Medical Sciences Limited
BSE: 543308 | NSE: KIMS
Sector: Healthcare | Industry: Hospital
01
ABOUT COMPANY
Krishna Institute of Medical Sciences Ltd. ( hereinafter as “KIMS“ or “The Company”) was originally incorporated on 26 July 1973 under the name “Jagjit Singh and Sons Private Limited” which was later changed to the name “Krishna Institute of Medical Sciences Limited” (KIMS) in 2nd January 2004 and in the same year, it was converted to a public company.
KIMS was founded by Dr. Bhaskara Rao Bollineni in Nellore, Andhra Pradesh with 200 beds. Until 2003, the entity was controlled by Jagjit Singh and his certain family members, after Dr. Bhaskara Rao Bollineni with with other individuals acquired the entire company.
KIMS provides healthcare services in the states named Maharashtra, Telangana, Kerala, Andhra Pradesh etc and it primarily focuses on tertiary and quaternary care. It also generates revenue through pharmacy as well.
| Particulars | FY 25 |
|---|---|
| Enterprise Value (₹ Crore) | 27,667 |
| EV/EBITDA | 35 |
| P/E | 66 |
| Revenue Growth % YoY | 21.5% |
| Gross Margin | 79.3% |
| EBITDA Margin | 25.8% |
| Net Margin | 13.7% |
Overview
| Year | State | Location / Facility | Bed Capacity | Model |
| 2025 | Andhra Pradesh | Guntur Shikara | 200 | O&M |
| 2025 | Andhra Pradesh | Guntur Chakra | 100 | O&M |
| 2025 | Maharashtra | Sangli | 350 | O&M |
| 2025 | Maharashtra | Thane | 300 | Standard |
| 2025 | Kerala | Kollam | 320 | Standard |
| 2025 | Karnataka | Mahadevapura | 450 | Standard |
| 2025 | Karnataka | Electronic City | 350 | Standard |
| 2026 | Telangana | Kompally | 200 | O&M |
| Planned | Telangana | Kondapur II | 800 | |
| Planned | Kerala | Palakkad | 210 | |
| Planned | Tamil Nadu | Chennai | 300 |
List of Services
| Department | Sub-Specialties / Services | Department | Sub-Specialties / Services |
| Brain | Neurology, Neurosurgery, Psychiatry, Neuro Rehabilitation | Skin | Dermatology, Cosmetology, Plastic and Reconstructive Surgery |
| Eyes | Ophthalmology | Orthodontics | Maxillo Facial Surgery |
| Gastro Intestinal Tract | Medical Gastroenterology, Surgical Gastroenterology, Hepatobiliary Pancreatic Surgery, Liver Transplant, Bariatric Surgery | Anaesthesia | OT Anaesthesia, Day care Anaesthesia, Pain Medicine |
| Genito Urinary Tract | Nephrology, Urology | General Specialties | Internal Medicine, General Surgery, Diabetology & Endocrinology |
| Cardiology | Cardiology | Pediatrics | Pediatrics & Pediatric Sub Specialties, Neonatology |
| Pulmonary | Interventional Pulmonology, Thoracic Surgery, Lung Transplant | Radiology | Imaging, Interventional Radiology |
| ENT | Ear, Nose, Throat, Head and Neck Surgery | Lab Services | Pathology, Microbiology, Biochemistry, Molecular Biology, Clinical Hematology |
| Obesity | Obesity, Medical Surgical and Radiation, BMT and Hematology | Critical Care Services | ICU, CTICU, SICU, NICU, PICU, Neuro ICU, ECMO ICU, Post Transplant ICU |
| Bones and Spine | Orthopedics, Arthroscopic Surgery, Spine Surgery, Ortho Rehabilitation | Hospital Infection Control | Clinical Infectious Diseases |
Domestic Presence of Hospitals
| State | City / Location | Operational Beds | Under Construction | Total Beds (Projected) |
| Andhra Pradesh | Anantapur | 250 | 250 | 500 |
| Guntur | 200 | 0 | 200 | |
| Kurnool | 200 | 0 | 200 | |
| Nellore | 250 | 0 | 250 | |
| Ongole | 350 | 50 | 400 | |
| Rajahmundry | 195 | 350 | 545 | |
| Srikakulam | 200 | 120 | 320 | |
| Vizag (KIMS Hospitals) | 300 | 0 | 300 | |
| Vizag (KIMS ICON) | 434 | 0 | 434 | |
| Karnataka | Bengaluru (PES) | 0 | 350 | 350 |
| Bengaluru (Soulspace) | 0 | 450 | 450 | |
| Kerala | Kannur | 189 | 0 | 189 |
| Kollam | 320 | 0 | 320 | |
| Maharashtra | Nagpur | 334 | 0 | 334 |
| Nashik | 325 | 0 | 325 | |
| Sangli | 350 | 0 | 350 | |
| Thane | 300 | 0 | 300 | |
| Telangana | Begumpet | 290 | 0 | 290 |
| Gachibowli | 237 | 0 | 237 | |
| Kondapur | 200 | 500 | 700 | |
| Secunderabad | 1000 | 0 | 1000 | |
| Asian Transcare | 60 | 0 | 60 | |
| MIPPL | 10 | 10 | ||
| Total | 5,994 | 2,070 | 8,064 |
Details of Subsidiaries
| State | Hospital/Unit | Ownership % | Category Type |
| Andhra Pradesh | AHPL Srikakulam | 65.9% | Doctor Partnership Hospitals |
| KIMS Kurnool | 55.0% | Doctor Partnership Hospitals | |
| KIMS Nellore | 100.0% | Units | |
| KIMS Ongole | 100.0% | Units | |
| KIMS QNRI Visakhapatnam | 100.0% | Wholly Owned Subsidiaries | |
| KIMS ICON Visakhapatnam | 51.0% | Doctor Partnership Hospitals | |
| KIMS Rajahmundry | 100.0% | Units | |
| KHPL Rajahmundry | 100.0% | Wholly Owned Subsidiaries | |
| KIMS Saveera Anantapur | 74.5% | Doctor Partnership Hospitals | |
| Karnataka | KIMS Hospitals Bengaluru | 80.0% | Doctor Partnership Hospitals |
| Kerala | KIMS Swastha Kerala | 100.0% | Wholly Owned Subsidiaries |
| Maharashtra | KIMS Thane | 100.0% | Units |
| KIMS-Manavata Nashik | 51.0% | Doctor Partnership Hospitals | |
| SPANV Nagpur | 69.3% | Doctor Partnership Hospitals | |
| Telangana | KIMS Secunderabad | 100.0% | Units |
| KHEPL Kondapur | 90.9% | Doctor Partnership Hospitals | |
| KIMS Sunshine Begumpet & Gachibowli | 76.2% | Doctor Partnership Hospitals | |
| MIPPL (Meda) Hyderabad | 51.0% | Doctor Partnership Hospitals |
02
Earning Calls Summary
Q1 FY 2027
Q1 Revenue Surges 36%; QIP Raises ₹1,500 Cr for Debt Repayment
Management opened noting the growth trajectory continued unabated, crossing the ₹1,000 crore revenue mark in Q3 FY26 and maintaining the same tempo. New units are performing well on expected lines, with Mahadevapura (Bangalore) achieving EBITDA breakeven in less than seven months.
Q1 FY27 REVENUE GROWTH
36.1% YoY to ₹1,196 crores
Q1 FY27 EBITDA GROWTH
20.1% YoY to ₹240 crores
IP VOLUME GROWTH (Q1 FY27)
26.6% YoY to 72,493 patients
Key Takeaway: Q1 FY27 total revenue grew 36.1% YoY to ₹1,196 crores with EBITDA of ₹240 crores (20.1% margin). The company successfully raised ₹1,500 crores through QIP (oversubscribed) and utilized ₹1,100 crores to reduce debt, while promoters committed ₹600 crores via preferential allotment.
Concall Notes
<style>
.paywall-card-container {
position: relative;
background: #F4F8FF;
border: 1.5px solid #D8E6FF;
border-radius: 20px;
padding: 42px 32px 28px 32px;
font-family: 'Inter', -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
box-shadow: 0 10px 30px rgba(15, 37, 64, 0.05);
overflow: hidden;
margin: 20px 0;
}
/* Top Center Premium Pill Tag */
.paywall-pill-tag {
position: absolute;
top: -1px;
left: 50%;
transform: translateX(-50%);
background: #0D50E8;
color: #FFFFFF;
font-size: 11px;
font-weight: 700;
letter-spacing: 0.8px;
padding: 5px 16px;
border-bottom-left-radius: 12px;
border-bottom-right-radius: 12px;
display: flex;
align-items: center;
gap: 6px;
box-shadow: 0 4px 10px rgba(13, 80, 232, 0.25);
z-index: 2;
}
/* Diagonal Corner Ribbon */
.paywall-corner-ribbon {
position: absolute;
top: 22px;
left: -35px;
background: #0D50E8;
color: #FFFFFF;
font-size: 10px;
font-weight: 800;
letter-spacing: 0.5px;
padding: 6px 40px;
transform: rotate(-45deg);
display: flex;
align-items: center;
gap: 5px;
box-shadow: 0 4px 8px rgba(13, 80, 232, 0.3);
z-index: 1;
}
/* Headings */
.paywall-title {
color: #0F172A;
font-size: 26px;
font-weight: 800;
text-align: center;
margin: 12px 0 6px 0;
line-height: 1.25;
}
.paywall-subtitle {
color: #64748B;
font-size: 14px;
text-align: center;
margin-bottom: 28px;
line-height: 1.4;
}
/* Feature Grid */
.paywall-grid {
display: grid;
grid-template-columns: repeat(3, 1fr);
gap: 16px 20px;
max-width: 820px;
margin: 0 auto 32px auto;
}
.paywall-grid-item {
display: flex;
align-items: center;
gap: 10px;
background: #FFFFFF;
padding: 10px 14px;
border-radius: 12px;
border: 1px solid #E5EFFF;
box-shadow: 0 2px 6px rgba(13, 80, 232, 0.03);
}
.paywall-icon-box {
width: 32px;
height: 32px;
border-radius: 8px;
background: #EEF4FF;
display: flex;
align-items: center;
justify-content: center;
flex-shrink: 0;
}
.paywall-check-icon {
width: 16px;
height: 16px;
border-radius: 50%;
background: #0D50E8;
display: flex;
align-items: center;
justify-content: center;
flex-shrink: 0;
}
.paywall-item-text {
font-size: 13px;
font-weight: 700;
color: #1E293B;
white-space: nowrap;
}
/* Bottom Footer CTA Box */
.paywall-footer {
display: flex;
align-items: center;
justify-content: space-between;
border-top: 1px solid #E0EBFF;
padding-top: 20px;
gap: 20px;
}
.paywall-footer-left {
display: flex;
align-items: center;
gap: 12px;
}
.paywall-shield-box {
width: 38px;
height: 38px;
border-radius: 10px;
background: #E2ECFF;
display: flex;
align-items: center;
justify-content: center;
flex-shrink: 0;
}
.paywall-footer-title {
font-size: 13px;
font-weight: 700;
color: #0F172A;
margin: 0 0 2px 0;
}
.paywall-footer-sub {
font-size: 12px;
color: #64748B;
margin: 0;
}
.paywall-footer-right {
display: flex;
flex-direction: column;
align-items: flex-end;
gap: 6px;
}
.paywall-cta-btn {
background: #0D50E8;
color: #FFFFFF !important;
font-size: 14px;
font-weight: 700;
padding: 12px 28px;
border-radius: 10px;
text-decoration: none !important;
display: inline-flex;
align-items: center;
gap: 8px;
box-shadow: 0 4px 14px rgba(13, 80, 232, 0.3);
transition: all 0.2s ease;
}
.paywall-cta-btn:hover {
background: #0A40BC;
transform: translateY(-1px);
box-shadow: 0 6px 18px rgba(13, 80, 232, 0.4);
}
.paywall-guarantee {
font-size: 11px;
color: #64748B;
display: flex;
align-items: center;
gap: 4px;
}
/* Responsive Rules */
@media (max-width: 850px) {
.paywall-grid {
grid-template-columns: repeat(2, 1fr);
}
}
@media (max-width: 600px) {
/* Scale & Reposition Ribbon on Mobile */
.paywall-corner-ribbon {
display: flex !important;
top: 14px !important;
left: -38px !important;
font-size: 8px !important;
padding: 4px 35px !important;
transform: rotate(-45deg) scale(0.85) !important;
}
.paywall-card-container {
padding: 50px 16px 20px 16px !important; /* Top space so badges clear text */
}
.paywall-title {
font-size: 19px !important;
margin-top: 12px !important;
}
.paywall-grid {
grid-template-columns: 1fr;
}
.paywall-footer {
flex-direction: column;
align-items: stretch;
gap: 16px;
text-align: center;
}
.paywall-footer-left {
flex-direction: column;
}
.paywall-footer-right {
align-items: center;
}
.paywall-cta-btn {
width: 100%;
justify-content: center;
}
}
</style>
<!-- HTML MARKUP -->
<div class="paywall-card-container">
<!-- Top Center Pill Tag -->
<div class="paywall-pill-tag">
<svg width="10" height="12" viewBox="0 0 12 14" fill="none" stroke="currentColor" stroke-width="2">
<rect x="1" y="5" width="10" height="8" rx="2"></rect>
<path d="M3 5V3.5a3 3 0 1 1 6 0V5"></path>
</svg>
PREMIUM
</div>
<!-- Top Left Corner Ribbon -->
<div class="paywall-corner-ribbon">
<svg width="10" height="10" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5">
<path d="M2 4l3 12h14l3-12-6 7-4-7-4 7-6-7z"></path>
</svg>
PREMIUM
</div>
<!-- Header Section -->
<div class="paywall-title">Unlock Comprehensive Analysis</div>
<div class="paywall-subtitle">Get deeper insights with detailed financials, forecasts, ratios & valuation</div>
<!-- Feature Grid -->
<div class="paywall-grid">
<!-- Item 1 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><path d="M18 20V10M12 20V4M6 20v-6"></path></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">Revenue & Gross Margin</span>
</div>
<!-- Item 2 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><path d="M21.21 15.89A10 10 0 1 1 8 2.83M22 12A10 10 0 0 0 12 2v10z"></path></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">EBITDA & Dividend</span>
</div>
<!-- Item 3 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><rect x="3" y="3" width="18" height="18" rx="2"></rect><path d="M3 9h18M9 21V9"></path></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">10Y Forecasted P&L</span>
</div>
<!-- Item 4 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><polyline points="23 6 13.5 15.5 8.5 10.5 1 18"></polyline><polyline points="17 6 23 6 23 12"></polyline></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">Balance Sheet</span>
</div>
<!-- Item 5 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><polygon points="12 2 2 7 12 12 22 7 12 2"></polygon><polyline points="2 17 12 22 22 17"></polyline><polyline points="2 12 12 17 22 12"></polyline></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">DuPont & Ratio Analysis</span>
</div>
<!-- Item 6 -->
<div class="paywall-grid-item">
<div class="paywall-icon-box">
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2.5"><path d="M16 16v1a2 2 0 0 1-2 2H3a2 2 0 0 1-2-2V7a2 2 0 0 1 2-2h11a2 2 0 0 1 2 2v1"></path><path d="M18 8h4a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-4v-8z"></path></svg>
</div>
<div class="paywall-check-icon"><svg width="10" height="8" viewBox="0 0 10 8" fill="none" stroke="#FFF" stroke-width="2"><path d="M1 4l2.5 2.5L9 1"></path></svg></div>
<span class="paywall-item-text">Valuation & more</span>
</div>
</div>
<!-- Bottom CTA Footer -->
<div class="paywall-footer">
<div class="paywall-footer-left">
<div class="paywall-shield-box">
<svg width="18" height="20" viewBox="0 0 24 24" fill="#0D50E8"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"></path></svg>
</div>
<div>
<div class="paywall-footer-title">Premium insights for smarter investing</div>
<p class="paywall-footer-sub">Upgrade to access institutional-quality research & analysis.</p>
</div>
</div>
<div class="paywall-footer-right">
<a href="https://equitalist.com/pricing" class="paywall-cta-btn">
<svg width="12" height="14" viewBox="0 0 12 14" fill="none" stroke="currentColor" stroke-width="2">
<rect x="1" y="5" width="10" height="8" rx="2"></rect>
<path d="M3 5V3.5a3 3 0 1 1 6 0V5"></path>
</svg>
Upgrade to Access
</a>
<div class="paywall-guarantee">
<svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="#0D50E8" stroke-width="2"><path d="M22 11.08V12a10 10 0 1 1-5.93-9.14"></path><polyline points="22 4 12 14.01 9 11.01"></polyline></svg>
30-Day Free Trial
</div>
</div>
</div>
</div>
Disclaimer
The research report presented here is for informational and research purposes only. It reflects our own views, assumptions, and analysis and is not intended as a recommendation, offer, or solicitation to buy, sell, or hold any security or asset. Please conduct your own due diligence and consult a qualified financial advisor before making any investment decision. Please check our Terms & Conditions page before investing.